For informational purposes only — not investment advice

← Back to signals

CB

LONGINSIDER SELLCONGRESS BUY

CHUBB LTD SWITZ

Research: Finviz ↗·Perplexity ↗

🗄 Viewing archived Q1 2026 data — frozen, no longer refreshed.

Funds
3
Score
2.45
vs SPY
-13.9%
Stock return (since Q-end)
+5.8%
SPY return (since Q-end)
+19.7%
Current price
$343.64
Days to cover (short int.)
2.7d
as of 2026-06-30

News Summary

Neutral

Chubb delivered strong H1 2026 financial performance with 14.6% YoY earnings growth in Q2, beat expectations, and raised guidance to $27–$28.50 EPS for full year 2026 with double-digit growth targets intact. However, significant headwinds are emerging: property market pricing has collapsed 25–40% in key markets, soft conditions are spreading to casualty lines, and the company is intentionally shrinking its large-account and E&S property business due to adverse pricing environment.

Red flags

  • •Property market pricing declined 25–40% in North America, London, and larger premiums, described by management as 'dumb' pricing
  • •Soft market conditions spreading beyond property to casualty lines with pricing failing to keep pace with loss costs
  • •Corporate runoff portfolio experienced $158 million adverse development from molestation-related claims
  • •Intentional shrinkage of large-account and E&S property business due to market conditions, signaling strategic retreat from certain segments

Funds Buying (3)

FundManagerShares Held∆ SharesPosition Value% of FundQoQStatus
Viking GlobalAndreas Halvorsen1.3M+281K$422M1.2%+28%Existing
Point72Steve Cohen32K+32K$11M<0.1%—NEW
Soros Fund ManagementSoros Family Office23K+23K$7M0.1%—NEW

Shares Held and Position Value reflect total quarter-end holdings. ∆ Shares is the change from the prior quarter. % of Fund is the position's share of the fund's reported equity portfolio — it drives the size weighting in the conviction score.

Portfolio Context

Where CB ranks in each buying fund's book, and the positions immediately around it. What a holding sits next to often says more about the thesis than the position size does.

Viking Global

position #34 of this fund's book

  1. 31ATI INC$485M
  2. 32CELESTICA INC$466M
  3. 33CAMDEN PPTY TR$461M
  4. 34CHUBB LTD SWITZ$422M
  5. 35ADAPTIVE BIOTECHNOLOGIES COR$416M
  6. 36BIOMARIN PHARMACEUTICAL INC$399M
  7. 37SEA LTD$392M

Values are quarter-end position sizes. Shown only for funds where CB ranks inside their 40 largest equity positions — below that, neighbouring names carry no signal. Adjacency is an inference about a fund's reasoning, not a disclosure of it.

Insider Activity

NameTitleTypeSharesPriceValueFiledSrc
Wayland Joseph FExecutive Vice President and*SELL9K$364.54$3.10M2026-07-28↗
Ortega Juan LuisExecutive Vice President*SELL4K$322.08$1.25M2026-06-08↗
Keogh John WPresident &COOSELL20K$321.45$6.49M2026-05-27↗
Keogh John WPresident &COOSELL3K$321.95$0.91M2026-05-27↗
ATIEH MICHAEL G—SELL578$329.53$0.19M2026-05-21↗

Congressional Trading

MemberChamberStateTypeAmount RangeTransaction DateFiledSrc
Alan Armstrongsenate—BUY$1,001 - $15,0002026-03-272026-07-21↗
Earlier trades (2) — dated outside this quarter's window, not counted in the badges
MemberChamberStateTypeAmount RangeTransaction DateFiledSrc
Kevin HernhouseOK01SELL$1,001 - $15,0002026-09-232026-10-13↗
Maria Elvira SalazarhouseFL27SELL$15,001 - $50,0002026-08-192026-09-09↗

Periodic Transaction Reports filed under the STOCK Act. Amounts are disclosed as ranges, not exact dollar figures. Members often file weeks or months after trading, so trades are placed by transaction date: the badges above count trades dated since Jan 1, 2026.